Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure
Background: Catheter ablation (CA) benefits atrial fibrillation (AF) patients with heart failure (HF). Brain natriuretic peptide (BNP), a marker of left-ventricular pressure load, may serve as a potential surrogate for predicting quality of life (QOL) in a broader range of patients. Methods: Within...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/2/407 |
| _version_ | 1797339680108183552 |
|---|---|
| author | Shin Kashimura Nobuhiro Ikemura Shun Kohsaka Yoshinori Katsumata Takehiro Kimura Daisuke Shinmura Kotaro Fukumoto Koji Negishi Ikuko Ueda Seiji Takatsuki Masaki Ieda |
| author_facet | Shin Kashimura Nobuhiro Ikemura Shun Kohsaka Yoshinori Katsumata Takehiro Kimura Daisuke Shinmura Kotaro Fukumoto Koji Negishi Ikuko Ueda Seiji Takatsuki Masaki Ieda |
| author_sort | Shin Kashimura |
| collection | DOAJ |
| description | Background: Catheter ablation (CA) benefits atrial fibrillation (AF) patients with heart failure (HF). Brain natriuretic peptide (BNP), a marker of left-ventricular pressure load, may serve as a potential surrogate for predicting quality of life (QOL) in a broader range of patients. Methods: Within the multicenter KiCS-AF registry, 491 AF patients underwent CA without clinical HF (e.g., documented history of HF, left ventricular ejection fraction ≤ 40%, or BNP levels ≥ 100 pg/mL). Participants, aged 61 ± 10 years, were categorized by baseline BNP quartiles. Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire assessments were assessed at baseline and 1 year. Results: A lower baseline BNP correlated with reduced AFEQT scores. Post CA, all groups showed significant AFEQT score improvements. The lower-BNP group displayed notable enhancements (18.2 ± 1.2, 15.0 ± 1.1, 12.6 ± 1.2, 13.6 ± 1.2, <i>p</i> < 0.005), especially in symptom and treatment concern areas. Even those with normal BNP levels (≤18.4 pg/mL) exhibited significant QOL improvements. Comparing paroxysmal AF (PAF) and non-PAF groups, the PAF group, especially with higher BNP levels, showed greater AFEQT score improvements. Conclusions: This study establishes BNP as a predictive marker for QOL enhancement in non-HF patients undergoing CA for AF. BNP levels represent AF stages, with individuals in earlier stages, especially within normal BNP levels, experiencing greater QOL improvements. |
| first_indexed | 2024-03-08T09:51:53Z |
| format | Article |
| id | doaj.art-5f3137d26c19438c9ff6f0f1da128fbc |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T09:51:53Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-5f3137d26c19438c9ff6f0f1da128fbc2024-01-29T14:01:30ZengMDPI AGJournal of Clinical Medicine2077-03832024-01-0113240710.3390/jcm13020407Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart FailureShin Kashimura0Nobuhiro Ikemura1Shun Kohsaka2Yoshinori Katsumata3Takehiro Kimura4Daisuke Shinmura5Kotaro Fukumoto6Koji Negishi7Ikuko Ueda8Seiji Takatsuki9Masaki Ieda10Department of Cardiology, Yokohama Municipal Citizen’s Hospital, 1-1, Mitsuzawa-nishicho, Kanagawa-ku, Yokohama 221-0855, JapanDepartment of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, JapanDepartment of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, JapanDepartment of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, JapanDepartment of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, JapanDepartment of Cardiology, Yokohama Municipal Citizen’s Hospital, 1-1, Mitsuzawa-nishicho, Kanagawa-ku, Yokohama 221-0855, JapanDepartment of Cardiology, Yokohama Municipal Citizen’s Hospital, 1-1, Mitsuzawa-nishicho, Kanagawa-ku, Yokohama 221-0855, JapanDepartment of Cardiology, Yokohama Municipal Citizen’s Hospital, 1-1, Mitsuzawa-nishicho, Kanagawa-ku, Yokohama 221-0855, JapanDepartment of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, JapanDepartment of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, JapanDepartment of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, JapanBackground: Catheter ablation (CA) benefits atrial fibrillation (AF) patients with heart failure (HF). Brain natriuretic peptide (BNP), a marker of left-ventricular pressure load, may serve as a potential surrogate for predicting quality of life (QOL) in a broader range of patients. Methods: Within the multicenter KiCS-AF registry, 491 AF patients underwent CA without clinical HF (e.g., documented history of HF, left ventricular ejection fraction ≤ 40%, or BNP levels ≥ 100 pg/mL). Participants, aged 61 ± 10 years, were categorized by baseline BNP quartiles. Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire assessments were assessed at baseline and 1 year. Results: A lower baseline BNP correlated with reduced AFEQT scores. Post CA, all groups showed significant AFEQT score improvements. The lower-BNP group displayed notable enhancements (18.2 ± 1.2, 15.0 ± 1.1, 12.6 ± 1.2, 13.6 ± 1.2, <i>p</i> < 0.005), especially in symptom and treatment concern areas. Even those with normal BNP levels (≤18.4 pg/mL) exhibited significant QOL improvements. Comparing paroxysmal AF (PAF) and non-PAF groups, the PAF group, especially with higher BNP levels, showed greater AFEQT score improvements. Conclusions: This study establishes BNP as a predictive marker for QOL enhancement in non-HF patients undergoing CA for AF. BNP levels represent AF stages, with individuals in earlier stages, especially within normal BNP levels, experiencing greater QOL improvements.https://www.mdpi.com/2077-0383/13/2/407atrial fibrillationbrain natriuretic peptidecatheter ablationnon-heart failurequality of life |
| spellingShingle | Shin Kashimura Nobuhiro Ikemura Shun Kohsaka Yoshinori Katsumata Takehiro Kimura Daisuke Shinmura Kotaro Fukumoto Koji Negishi Ikuko Ueda Seiji Takatsuki Masaki Ieda Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure Journal of Clinical Medicine atrial fibrillation brain natriuretic peptide catheter ablation non-heart failure quality of life |
| title | Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure |
| title_full | Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure |
| title_fullStr | Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure |
| title_full_unstemmed | Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure |
| title_short | Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure |
| title_sort | clinical utility of baseline brain natriuretic peptide levels on health status outcomes after catheter ablation for atrial fibrillation in individuals without heart failure |
| topic | atrial fibrillation brain natriuretic peptide catheter ablation non-heart failure quality of life |
| url | https://www.mdpi.com/2077-0383/13/2/407 |
| work_keys_str_mv | AT shinkashimura clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT nobuhiroikemura clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT shunkohsaka clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT yoshinorikatsumata clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT takehirokimura clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT daisukeshinmura clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT kotarofukumoto clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT kojinegishi clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT ikukoueda clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT seijitakatsuki clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure AT masakiieda clinicalutilityofbaselinebrainnatriureticpeptidelevelsonhealthstatusoutcomesaftercatheterablationforatrialfibrillationinindividualswithoutheartfailure |